{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T16:02:28Z","timestamp":1790006548446,"version":"4.0.1"},"reference-count":35,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,2]],"date-time":"2024-10-02T00:00:00Z","timestamp":1727827200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","onlinecjc.ca","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Canadian Journal of Cardiology"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.cjca.2024.09.025","type":"journal-article","created":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T12:21:13Z","timestamp":1736166073000},"page":"128-136","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Cost-Effectiveness of Semaglutide in Patients With Obesity and Cardiovascular Disease"],"prefix":"10.1016","volume":"41","author":[{"given":"Elissa","family":"Rennert-May","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Braden","family":"Manns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Clement","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eldon","family":"Spackman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Collister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glen","family":"Sumner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenine","family":"Leal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.H.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3539-7485","authenticated-orcid":false,"given":"Derek S.","family":"Chew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cjca.2024.09.025_bib2","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1001\/archinte.167.16.1720","article-title":"Association of overweight with increased risk of coronary heart disease partly independent of blood pressure and cholesterol levels: a meta-analysis of 21 cohort studies including more than 300 000 persons","volume":"167","author":"Bogers","year":"2007","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.cjca.2024.09.025_bib3","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1614362","article-title":"Health effects of overweight and obesity in 195 countries over 25 years","volume":"377","author":"GBD 2015 Obesity Collaborators","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2024.09.025_bib4","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1038\/s41591-022-02026-4","article-title":"Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial","volume":"28","author":"Garvey","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.cjca.2024.09.025_bib5","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2024.09.025_bib6","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2024.09.025_bib7","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials","volume":"9","author":"Sattar","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.cjca.2024.09.025_bib8","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1016\/j.cjca.2023.07.007","article-title":"Biology and clinical use of glucagon-like-peptide-1 receptor agonists in vascular protection","volume":"39","author":"Yau","year":"2023","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjca.2024.09.025_bib9","article-title":"Cardiovascular effectiveness of sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists in older patients in routine clinical care with or without history of atherosclerotic cardiovascular diseases or heart failure","volume":"11","author":"Htoo","year":"2022","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.cjca.2024.09.025_bib10","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/j.cjca.2022.04.029","article-title":"2022 Canadian Cardiovascular Society guideline for use of GLP-1 receptor agonists and SGLT2 inhibitors for cardiorenal risk reduction in adults","volume":"38","author":"Mancini","year":"2022","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjca.2024.09.025_bib11","doi-asserted-by":"crossref","first-page":"e278","DOI":"10.1097\/MJT.0000000000000282","article-title":"Potential clinical and economic impact of switching branded medications to generics","volume":"24","author":"Straka","year":"2017","journal-title":"Am J Ther"},{"key":"10.1016\/j.cjca.2024.09.025_bib12","doi-asserted-by":"crossref","first-page":"152","DOI":"10.21037\/atm-22-200","article-title":"Cost-effectiveness analysis of 4 GLP-1RAs in the treatment of obesity in a US setting","volume":"10","author":"Hu","year":"2022","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.cjca.2024.09.025_bib13","first-page":"740","article-title":"Cost-effectiveness analysis of semaglutide 2.4 mg for the treatment of adult patients with overweight and obesity in the United States","volume":"28","author":"Kim","year":"2022","journal-title":"J\u00a0Manag Care Spec Pharm"},{"key":"10.1016\/j.cjca.2024.09.025_bib14","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1038\/s41366-024-01467-w","article-title":"Cost-effectiveness of weight-management pharmacotherapies in Canada: a societal perspective","volume":"48","author":"Olivieri","year":"2024","journal-title":"Int J Obes (Lond)"},{"key":"10.1016\/j.cjca.2024.09.025_bib15","first-page":"1","article-title":"CADTH reimbursement recommendation semaglutide (Wegovy)","volume":"2","year":"2022","journal-title":"Can J Health Technol"},{"key":"10.1016\/j.cjca.2024.09.025_bib16","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jval.2021.10.008","article-title":"Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 2022 explanation and elaboration: a report of the ISPOR CHEERS II good practices task force","volume":"25","author":"Husereau","year":"2022","journal-title":"Value Health"},{"key":"10.1016\/j.cjca.2024.09.025_bib17","series-title":"Guidelines for the Economic Evaluation of Health Technologies: Canada","year":"2017"},{"key":"10.1016\/j.cjca.2024.09.025_bib18","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1146\/annurev.publhealth.18.1.105","article-title":"Survival analysis in public health research","volume":"18","author":"Lee","year":"1997","journal-title":"Annu Rev Public Health"},{"key":"10.1016\/j.cjca.2024.09.025_bib19","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1002\/sim.1203","article-title":"Flexible parametric proportional-hazards and proportional-odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects","volume":"21","author":"Royston","year":"2002","journal-title":"Stat Med"},{"key":"10.1016\/j.cjca.2024.09.025_bib20","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/j.jval.2019.03.017","article-title":"Extrapolating survival data using historical trial-based a priori distributions","volume":"22","author":"Soikkeli","year":"2019","journal-title":"Value Health"},{"key":"10.1016\/j.cjca.2024.09.025_bib21","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1080\/01621459.1986.10478316","article-title":"Alternative models for the heterogeneity of mortality risks among the aged","volume":"81","author":"Manton","year":"1986","journal-title":"J\u00a0Am Stat Assoc"},{"key":"10.1016\/j.cjca.2024.09.025_bib22","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/00005650-200503000-00003","article-title":"US valuation of the EQ-5D health states: development and testing of the D1 valuation model","volume":"43","author":"Shaw","year":"2005","journal-title":"Med Care"},{"key":"10.1016\/j.cjca.2024.09.025_bib23","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.orcp.2023.09.006","article-title":"Health care cost of severe obesity and obesity-related comorbidities: a retrospective cohort study from Alberta, Canada","volume":"17","author":"Butalia","year":"2023","journal-title":"Obes Res Clin Pract"},{"key":"10.1016\/j.cjca.2024.09.025_bib25","series-title":"The Consumer Price Index (Catalogue no. 62-001-X). Vol 95","year":"2016"},{"key":"10.1016\/j.cjca.2024.09.025_bib26","series-title":"Statistical analysis of cost-effectiveness data","author":"Willan","year":"2006"},{"key":"10.1016\/j.cjca.2024.09.025_bib27","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1001\/jama.2009.1409","article-title":"Using effectiveness and cost-effectiveness to make drug coverage decisions: a comparison of Britain, Australia, and Canada","volume":"302","author":"Clement","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.cjca.2024.09.025_bib28","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/oby.2002.14","article-title":"Obesity and long-term clinical and economic outcomes in coronary artery disease patients","volume":"10","author":"Eisenstein","year":"2002","journal-title":"Obes Res"},{"key":"10.1016\/j.cjca.2024.09.025_bib29","doi-asserted-by":"crossref","first-page":"445","DOI":"10.2147\/CEOR.S264589","article-title":"Can standard health technology assessment approaches help guide the price of orphan drugs in Canada? A review of submissions to the Canadian Agency for Drugs and Technologies in Health common drug review","volume":"12","author":"Balijepalli","year":"2020","journal-title":"Clinicoecon Outcomes Res"},{"key":"10.1016\/j.cjca.2024.09.025_bib30","doi-asserted-by":"crossref","first-page":"e984","DOI":"10.1161\/CIR.0000000000000973","article-title":"Obesity and cardiovascular disease: a scientific statement from the American Heart Association","volume":"143","author":"Powell-Wiley","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2024.09.025_bib31","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1146\/annurev-nutr-071714-034434","article-title":"Health benefits of long-term weight-loss maintenance","volume":"35","author":"Rueda-Clausen","year":"2015","journal-title":"Annu Rev Nutr"},{"key":"10.1016\/j.cjca.2024.09.025_bib33","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1111\/dom.13172","article-title":"Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy","volume":"20","author":"Vilsboll","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.cjca.2024.09.025_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.dsx.2023.102834","article-title":"Semaglutide and cancer: a systematic review and meta-analysis","volume":"17","author":"Nagendra","year":"2023","journal-title":"Diabetes Metab Syndr"},{"key":"10.1016\/j.cjca.2024.09.025_bib35","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1111\/dom.15382","article-title":"Glucagon-like peptide-1 receptor agonists and risk of thyroid cancer: a systematic review and meta-analysis of randomized controlled trials","volume":"26","author":"Silverii","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.cjca.2024.09.025_bib36","article-title":"Cost-utility of catheter ablation for atrial fibrillation in patients with heart failure: an economic evaluation","volume":"10","author":"Lau","year":"2021","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.cjca.2024.09.025_bib37","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s41669-017-0061-0","article-title":"The healthcare cost burden of acute myocardial infarction in Alberta, Canada","volume":"2","author":"Tran","year":"2018","journal-title":"Pharmacoecon Open"},{"key":"10.1016\/j.cjca.2024.09.025_bib38","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.1161\/STROKEAHA.123.043369","article-title":"Attributable costs of stroke in Ontario, Canada and their variation by stroke type and social determinants of health","volume":"54","author":"Vyas","year":"2023","journal-title":"Stroke"}],"container-title":["Canadian Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X24010055?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X24010055?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,23]],"date-time":"2025-02-23T21:32:41Z","timestamp":1740346361000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0828282X24010055"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S0828282X24010055"],"URL":"https:\/\/doi.org\/10.1016\/j.cjca.2024.09.025","relation":{},"ISSN":["0828-282X"],"issn-type":[{"value":"0828-282X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-Effectiveness of Semaglutide in Patients With Obesity and Cardiovascular Disease","name":"articletitle","label":"Article Title"},{"value":"Canadian Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cjca.2024.09.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc. on behalf of the Canadian Cardiovascular Society.","name":"copyright","label":"Copyright"}]}}